Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.
Summary
Host Dave Knapp discusses Novo Nordisk’s potential shift toward synthetic semaglutide production in China, contrasting this with their years of anti-compounding rhetoric. The episode also covers Pfizer discontinuing GLP-1 assets from its Metsera acquisition and blocking GIP receptors. Finally, Knapp previews upcoming Eli Lilly earnings calls, focusing on retatrutide updates and trial statuses.
Topics discussed
Intro: Novo Nordisk's China strategy and studio updates
Sponsor segment: VOA Fit individualized care
Novo's long-standing argument against compounded semaglutide
Pfizer discontinues Metsera GLP-1 assets after acquisition
The GIP paradox: Agonists vs antagonists in weight loss
Novo exploring synthetic semaglutide in China
Upcoming Eli Lilly earnings call and Retatrutide news
Outro and sponsor ads: USAA and LifeLock
Listen ad-free on Castria